期刊文献+

依度沙班片的处方工艺筛选与优化

Study on the Prescription and Technology of Edaxaban Tablets
下载PDF
导出
摘要 目的:立足工业化生产,开发依度沙班片的处方工艺。方法:以原研药依度沙班片溶出曲线作为指标,对处方组成、制备工艺进行筛选,同时对其中关键的因素粘合剂进行优化。结果:最终确定的处方为依度沙班30 mg,甘露醇105 mg,预胶化淀粉45 mg,交联聚维酮8.0 mg,羟丙基纤维素(HPC-SSL)4.0%水溶液适量,欧巴代胃溶型包衣粉增重2%~3%;工艺中关键参数优化结果为湿法制粒时间10 min;依照此法制备得到的依度沙班片与原研品的溶出行为相似。结论:本品处方工艺设计合理,具有可操作性,可以进行大规模的工业化生产。 Objective:Based on industrial production,develop the prescription technology of Edoxaban tablets.Methods:Using the original edoxaban tablet dissolution profile as an indicator,the formulation composition and formulation process were screened,and the key factors of the binder were optimized.Results:The final formulation was edoxaban 30 mg,mannitol 105 mg,pregelatinized starch 45 mg,crospovidone 8.0 mg,hydroxypropyl cellulose(HPC-SSL)4.0%aqueous solution,Coating powder 2%~3%.The optimization result of the key parameters in the process is that the wet granulation time is 10 minutes.The dissolution behavior of edoxaban tablets prepared according to this method is similar to the original research product.Conclusion:The formulation of this product has reasonable design and can be used for large-scale industrial production.
作者 黄洋 臧萍 钟雪彬 李纬 Huang Yang;Zang Ping;Zhong Xuebin;Li Wei(Nanjing Changao Pharmaceutical Science and Technology Limited,Nanjing 210038,China)
出处 《山东化工》 CAS 2021年第7期55-56,59,共3页 Shandong Chemical Industry
关键词 依度沙班片 溶出曲线 处方筛选 工业化生产 edoxaban tablets dissolution profile prescription screening industrial production
  • 相关文献

参考文献4

二级参考文献75

  • 1鞠成伟,王连生,杨翔,马根山,华子春,高兴亚.人胎盘抗凝蛋白变体的抗凝与抗栓作用[J].中华血液学杂志,2004,25(9):540-543. 被引量:8
  • 2于爱平,石炳兴,董春娜,蒋中华,吴祖泽.人组织型纤溶酶原激活剂-水蛭素融合基因的构建及其在毕赤酵母中的表达[J].生物工程学报,2005,21(4):553-557. 被引量:6
  • 3邱贵兴,戴尅戎,杨庆铭,裴福兴,陈百成,曾炳芳,陈安民,王坤正,王继芳,余楠生,周乙雄,孙天胜,刘强,胡永成.中国骨科大手术深静脉血栓形成预防专家建议[J].中国医刊,2006,41(1):31-35. 被引量:60
  • 4张传领,于爱平,靳继德,吴祖泽.水蛭素融合蛋白研究进展[J].中国实验血液学杂志,2007,15(1):215-218. 被引量:5
  • 5Zhang P, Huang W, Wang L, et al. Discovery of betrixaban (PRT054021),N-(5-chloropyridin-2-yl)-2-(4- (N,N-dimethylcarbamimidoyl) benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor X a inhibitor [J]. Bioorg Med Chem Lett, 2009, 19(8): 2179-2185.
  • 6Turpie A G, Bauer K A, Davidson B L, et al. A randomized evaluation of betrixaban, an oral factor X a inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT) [J]. Thromb Haemost, 2009, 101(1): 68-76.
  • 7Eriksson B I, Turpie A G, Lassen M R, et al. A dose escalation study of YMI50, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery [J]. J Thromb Haemost, 2007, 5(8): 1660-1665.
  • 8Eriksson B I, Turpie A C, Lassen M R, et al. Prevention of venous thromboembolism with an oral factor X a inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2) [J]. J Thromb Haemost, 2010, 8(4): 714-721.
  • 9Fuji T, Fujita S, Tachibana S, et al. A dose-ranging study evaluating the oral factor X a inlaibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty [J]. J Thromb Haemost, 2010, 8(11): 2458-2468.
  • 10Kawamura M, Konishi N, Hiroe K, et al. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor X a inhibitor, in a rabbit model of venous thrombosis [J]. J Cardiovasc Pharmacol, 2010, 56(2): 156-161.

共引文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部